APN Inhibitor Bestatin Induces MM Cell Differentiation Through the CD79B/BTK/STAT3 Pathway

Differentiation therapy holds significant potential for the treatment of multiple myeloma (MM). We previously identified that the aminopeptidase N (APN) inhibitor Bestatin promotes MM cell differentiation. Herein, we elucidate the underlying molecular mechanisms of this process. Utilizing MM1.S, U26...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Xiaoke Wang, Chunyan Fang, Shanyu Li, Huakai Zeng, Junyi Liu, Xinwei Duan, Xiaoyi Zhang, Wenyan Jiang, Xuejian Wang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2026-05-01
Edice:	Cells
Témata:	multiple myeloma differentiation Bestatin CD79B/BTK
On-line přístup:	https://www.mdpi.com/2073-4409/15/10/949
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!